Form 4: Bristol-Myers Squibb Director Michael McMullen Receives Deferred Share Units as Compensation

Bristol-Myers Squibb Company's Director, Michael R. McMullen, was granted 728.359 Deferred Share Units as part of his compensation, increasing his total beneficial ownership to 9,171.659 units.

Summary

• Director Michael R. McMullen acquired 728.359 Deferred Share Units (DSUs) on June 30, 2025.
• The acquisition was part of a compensation plan, with a transaction price of $0 per unit.
• Following this transaction, McMullen's total beneficial ownership of DSUs stands at 9,171.659 units.
• Each DSU is convertible into one share of Bristol-Myers Squibb common stock upon settlement.
• DSUs become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
• The reported DSUs include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The document reports a routine grant of deferred share units to a director, which is a positive signal of alignment between management and shareholders, but does not indicate any extraordinary operational or financial performance.

Positives

• The grant of Deferred Share Units aligns the director's financial interests with those of the shareholders, as the value of the units is tied to the company's stock performance.
• The acquisition of additional equity by a director can signal confidence in the company's long-term prospects.

Future Outlook

Deferred Share Units held by Director Michael R. McMullen will convert into shares of common stock upon his cessation as a director or at a future date he previously specified.

Industry Context

The grant of Deferred Share Units is a common practice for compensating non-employee directors in large publicly traded companies, particularly within the pharmaceutical industry, to align their interests with long-term shareholder value.

Comparison to Industry Standards

• Deferred Share Units (DSUs) are a standard component of non-employee director compensation packages across various industries, including pharmaceuticals, technology, and finance.
• This compensation structure is comparable to practices at peer companies like Pfizer Inc. (PFE) or Merck & Co., Inc. (MRK), which also utilize equity-based awards to compensate their non-executive board members.

Corporate Governance

Related Party Transactions

• The grant of Deferred Share Units to Director Michael R. McMullen constitutes a related-party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of equity-based compensation to a director helps align the director's interests with those of the shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The Deferred Share Units will be converted into common stock shares upon the reporting person ceasing to be a director or at a future specified date.

Key Dates

Recommendation

Keywords

Bristol-Myers Squibb, BMY, Deferred Share Units, Director Compensation, Insider Ownership, SEC Form 4, Equity Grant, Pharmaceuticals